Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?

Archives of Neurology

Volumn 63, Issue 4, 2006, Pages 557-560

  De Carvalho, Mamede ^a,c,d   Swash, Michael ^b,e  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Centro de Estudos Egas Moniz   (Portugal)

^d INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^e ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL RESEARCH; METHODOLOGY; MOTOR UNIT; MOTOR UNIT NUMBER ESTIMATION; NEUROLOGIC EXAMINATION; NEUROPHYSIOLOGIC INDEX; NEUROPHYSIOLOGY; OUTCOME ASSESSMENT; PATIENT SELECTION; PORTUGAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS; DISABILITY EVALUATION; DISEASE PROGRESSION; ELECTRODIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; PATIENT SELECTION; PERIPHERAL NERVES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 33645743035     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.4.557     Document Type: Article

References (11)

1. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain. 1995;118:707-719.
2. Stambler N, Charatan M, Cedarbaum J. Prognostic indicators of survival in ALS. Neurology. 1998;50:66-72.
3. Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25:709-714.
4. Kaufmann P, Levy G, Thompson JLD, et al. The ALS-FRS predicts survival time in an ALS clinic population. Neurology. 2005;64:38-43.
5. Armon C, Brandstater ME. Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle Nerve. 1999;22:1571-1575.
6. de Carvalho M, Scotto M, Lopes A, Swash M. Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis. Muscle Nerve. 2003;28:630-633.
7. de Carvalho M, Scotto M, Lopes A, Swash M. Quantifying progression in amyotrophic lateral sclerosis. Neurology. 2005;64:1783-1785.
8. Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-300.
9. de Carvalho M, Chio A, Dengler R, Hecht M, Weber M, Swash M. Neurophysiological measures in amyotrophic lateral sclerosis: markers of disease progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:17-28.
10. Matthews JNS. An Introduction to Randomized Controlled Clinical Trials. London, England: Arnold; 2000.
11. Festoff BW, Suo Z, Citron BA. Prospects for the pharmacotherapy of amyotrophic lateral sclerosis: old strategies and new paradigms for the third millennium. CNS Drugs. 2003;17:699-717.